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Brefeldin ARecent evidence suggests that transmembrane domain (TMD) interactions are essential for HIV-1 Vpu-
mediated antagonism of the restriction factor BST-2/tetherin. We made Vpu TMD mutants to study the
mechanism of BST-2 antagonism. Vpu-I17A, -A18F, -W22L, and -S23L co-localized with BST-2 within
endosomal membranes while effectively enhancing virion release and down-regulating surface BST-2.
However, Vpu-A18H was conﬁned to an endoplasmic reticulum (ER)-like distribution, resulting in impaired
down-regulation of BST-2 and reduced virion release. Brefeldin A conﬁned wild type Vpu to the ER, resulting
in a similarly impaired phenotype, as did the addition of a C-terminal ER-retention signal to Vpu. We
determined the half-life of cell-surface BST-2 to be ~8 hours, whereas Vpu mediated an ~80% reduction of
surface BST-2 within 6 hours, suggesting that TMD interactions between Vpu and BST-2 occur within post-ER
membranes to directly and rapidly remove BST-2 from the cell surface and relieve restricted virion release.Diego, 9500 Gilman Drive, La
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Several interferon (IFN)-inducible innate host restriction
factors reduce the efﬁciency of Human Immunodeﬁciency Virus
type-1 (HIV-1) replication in vitro, including APOBEC3G (A3G)
(Sheehy et al., 2002), APOBEC3F (A3F) (Huthoff and Towers, 2008),
TRIM5α (Stremlau et al., 2004), and BST-2/CD317/tetherin (Neil et al.,
2008; Van Damme et al., 2008). BST-2 traps fully mature HIV-1 virus
particles on the surface of infected cells, although the exact
mechanism of restriction is unclear (Neil et al., 2008; Perez-Caballero
et al., 2009). The sequestration of virus particles by BST-2 is not
unique to HIV-1 and other retroviruses; BST-2 has been demonstrated
to trap other enveloped viruses including KSHV, Lassa, as well as Ebola
and Marburg virus-like particles (VLPs) (Jouvenet et al., 2009;
Kaletsky et al., 2009; Mansouri et al., 2009; Sakuma et al., 2009).
KSHV, Ebola, SIV, HIV-2, and HIV-1 have each evolved proteins to
counteract the restrictive properties of BST-2 including K5 (KSHV)
(Bartee et al., 2006; Mansouri et al., 2009), Ebola glycoprotein
(Kaletsky et al., 2009), Nef (SIV) (Jia et al., 2009), Env (HIV-2 andSIV) (Gupta et al., 2009b; Le Tortorec and Neil, 2009) and Vpu (HIV-1)
(Neil et al., 2008; Van Damme et al., 2008).
BST-2 is a 30-36-kDa, 180-amino acid, heterogeneously glycosy-
lated dimeric type II transmembrane protein (Kupzig et al., 2003;
Ohtomo et al., 1999). The ectodomain of BST-2 consists of α-helices
that form a coiled-coil (Hinz et al., 2010; Schubert et al., 2010). The
extracellular domain also contains two N-linked glycosylation sites
and is modiﬁed by a glycosyl phosphatidyl inositol (GPI) membrane-
anchor at the C-terminus (Kupzig et al., 2003). The N-terminal
cytoplasmic domain contains a conserved YxY sequence important for
clathrin-mediated endocytosis (Masuyama et al., 2009; Rollason et al.,
2007), non-human primate BST-2 orthologues contain a DDIWK
sequence for responsiveness to SIV Nef (Jia et al., 2009; Zhang et al.,
2009), and human BST-2 also contains a KxxK sequence whose lysine
residues are ubiquitinated by K5 (Mansouri et al., 2009). Comparative
analysis of BST-2 orthologs and site directed mutagenesis revealed
that the transmembrane domain (TMD) of human BST-2 contains
several residues that render the protein sensitive to Vpu (Gupta et al.,
2009a; Jia et al., 2009; McNatt et al., 2009; Rong et al., 2009),
suggesting that TMD–TMD interactions may play a signiﬁcant role in
the mechanism of the antagonism of BST-2 by Vpu.
Vpu is a 16-kDa, 81-amino acid, homo-oligomeric type I trans-
membrane phosphoprotein that causes the ER-associated degradation
Table 1
Site-speciﬁc amino acid composition at Vpu positions 17, 18, 22, and 23 based on1563
sequences*.
p17 Frequency
(N)
p18 Frequency
(N)
p22 Frequency
(N)
p23 Frequency
(N)
I 63 (991) A 95 (1479) W 99 (1551) T 61 (956)
L 27 (426) V 4 (55) X b1 (3) S 25 (387)
A 8 (128) T 1 (19) G b1 (1) I 11 (117)
V b1 (10) G b1 (6) R b1 (1) A 1 (22)
X b1 (4) X b1 (3) Y b1 (1) V b1 (10)
S b1 (2) C b1 (1) X b1 (4)
M b1 (1) N b1 (1) F b1 (3)
T b1 (1) D b1 (1)
G b1 (1)
L b1 (1)
P b1 (1)
I17A 8% A18H 0% W22L 0% S23L b1%
*Amino acid composition calculated using all available HIV-1 M group sequences in the
Los Alamos National Lab HIV Sequence Database (one sequence included per host).
Positions are numbered according to the NL4-3 reference sequence. Residues at each
site are listed from most to least frequent. Numbers in parentheses indicated total
number of sequences in the database with the listed amino acid. Gaps and stop codons
were excluded from analysis.
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1996a; Strebel et al., 1988). Vpu also enhances virion release
(Schubert et al., 1996a,b). The cytoplasmic domain (CD) of Vpu
contains a DSGxxS phosphoserine motif that recruits β-TrCP and an
SCF E3 ubiquitin ligase complex that induces the ERAD of CD4
(Margottin et al., 1998; Schubert et al., 1996a). The CD of Vpu plays a
signiﬁcant role in down-regulating BST-2 from the cell surface and
relieving BST-2-associated restriction, also via a mechanism partially
involving the recruitment of β-TrCP and the SCF E3 ubiquitin ligase
complex (Douglas et al., 2009; Mitchell et al., 2009; Tokarev et al.,
2011; Van Damme et al., 2008). However, the speciﬁc pathway used
to down-regulate BST-2 is unclear, with evidence for an ERAD-like
mechanism associated with degradation of BST-2 (Mangeat et al.,
2009), endosomal trafﬁcking mechanisms associated with speciﬁc
removal of BST-2 from the cell surface (Mitchell et al., 2009), and
entrapment of BST-2 within the trans-Golgi network (Dube et al.,
2010; Hauser et al., 2010).
The TMD of Vpu forms homo-oligomeric cation-selective ion
channels which were proposed to enhance virion release, a notion
supported by the observation that the TMD sequence is required for
both the enhancement of virion release and ion channel activity
(Lopez et al., 2002; Schubert et al., 1996a,b). However, the discovery
of BST-2 as the restriction factor antagonized by Vpu rendered the
functional signiﬁcance of Vpu's ion channel activity unclear. The TMD
of Vpu is required for the down-regulation of BST-2 from the cell
surface as well as for counteraction of BST-2mediated restriction (Van
Damme et al., 2008). The recent evidence that speciﬁc BST-2 TMD
residues are necessary for sensitivity to Vpu further support the
notion that the TMDs of Vpu and BST-2 interact (Dube et al., 2010;
Gupta et al., 2009a; Jia et al., 2009; McNatt et al., 2009; Rong et al.,
2009).
Here, we show that mutating the TMD of Vpu affects both the
protein's subcellular localization and its ability to antagonize BST-2.
Several of the Vpu mutants tested (Vpu-I17A, -A18F, -W22L, and
-S23L) effectively co-localized with BST-2, enhanced virion release,
and down-regulated BST-2 from the cell surface. Two of these
mutants, Vpu-W22L and -S23L, were previously evaluated for their
ion channel activity (Mehnert et al., 2008). Vpu-S23L was reportedly
defective (Mehnert et al., 2008), indicating that ion channel activity
may be unrelated to BST-2 antagonism. The Vpu mutant A18H
inefﬁciently enhanced virion release, inefﬁciently down-regulated
BST-2 from the cell surface, appeared to be trapped in the ER, and co-
localized poorly with BST-2, although it was able to down-regulate
CD4 from the cell surface. We could recapitulate the A18H phenotype
in the case of wild type Vpu using the fungal metabolite brefeldin A
(BFA) to block egress of Vpu from the ER, or by appending an ER-
retention signal to the C-terminus of Vpu. We determined that BST-2
on the cell surface is relatively long-lived, with a half-life of
approximately 8 hours, whereas Vpu mediated an 80% reduction of
surface BST-2 as soon as 6 hours after the onset of expression. These
data together suggest that the Vpu-mediated antagonism of BST-2
occurs independently of ion channel activity, within a post-ER
compartment, and likely involves primarily the targeting of existing
rather than newly synthesized BST-2 to directly decrease surface
levels and relieve restricted virion release.
Results
Rationale of site-directed mutations and the frequency of Vpu
polymorphisms in group M isolates of HIV-1
To evaluate the contribution of Vpu TMD domain residues, four
Vpu TMDmutant-proteins were initially generated: Vpu-I17A, -A18H,
-W22L, and -S23L. These four mutants were chosen based on previous
literature suggesting potential effects on the ion-channel activity of
Vpu (Mehnert et al., 2008; Park et al., 2003). Although Vpu-I17A andVpu-A18H have not been characterized for ion-channel activity, the
proximity of the mutations to a hinge region or kink in the middle of
the α-helical Vpu TMD suggested that these mutations might alter
channel activity (Park et al., 2003). Vpu-W22L was previously char-
acterized as a functional ion-channel, although the durations between
the open and closed conformations in artiﬁcial lipid bilayers were
prolonged compared to the wild type Vpu (Mehnert et al., 2008). In
contrast, Vpu-S23L was previously characterized as defective for ion-
channel activity (Mehnert et al., 2008).
To assess the conservation of these residues, an alignment of Vpu
TMDs was performed using all of the available 1563 HIV-1 group M
sequences from the Los Alamos National Lab HIV Sequence Database
(Table 1). The alignment indicated that residues A18 and W22 are
highly conserved, with frequencies greater than 95%, while residues
I17 and S23 occur at lower frequencies, 63% for I17 and 25% for S23.
Three of the generated substitutions exhibited frequencies of less than
1% [A18H (0%), W22L (0%), and S23L (0.06%)], while the I17A sub-
stitution appeared as a naturally occurring polymorphism with a
frequency of 8.2%. Notably, residue 23 occurred as an isoleucine in 11%
of sequences.
Vpu-A18H inefﬁciently down-regulates the expression of BST-2 at the
cell surface
The precise mechanism by which Vpu antagonizes the restriction
factor BST-2 to enhance HIV-1 virion release has yet to be elucidated,
although substantial evidence indicates a correlation between the Vpu-
mediated down-regulation of BST-2 from the cell surface and the
enhancement of virion release. To further test this correlation, we
assayed the ability of each of the Vpu TMD mutant-proteins to down-
regulate BST-2 from the cell surface. Cells were co-transfected with a
plasmid expressing codon-optimized Vpu along with a plasmid
expressing GFP to indicate transfection efﬁciency. Cells were stained
for surface BST-2 and analyzed by two-color ﬂow cytometry (Fig. 1A, in
which the relative cell number vs. BST-2ﬂuorescence intensity is shown
for the GFP-positive cells). The levels of surface BST-2 were reduced
approximately 10-fold by the expression of wild type Vpu after
24 hours. Similar levels of down-regulation of surface BST-2 were
achieved with the expression of the Vpu TMD mutant-proteins Vpu-
I17A, -W22L, and -S23L (Fig. 1C). The expression of Vpu-2/6, which
contains two substitutions (S52N and S56N) in the DSGXXS motif
within the cytoplasmic domain, resulted in an intermediate down-
regulation of surface BST-2 expression consistentwithpreviousﬁndings
(Fig. 1A and C). Most interestingly, Vpu-A18H was dramatically
Fig. 1. Vpu-A18H inefﬁciently down-regulates surface BST-2 expression. Cells (HeLa) were transfected with either an empty vector plasmid or a plasmid expressing codon-optimized
Vpu (160 ng), along with a plasmid expressing GFP (80 ng) as a transfection marker. The next day, the cells were simultaneously stained for surface BST-2 and surface CD4 then
analyzed by three-color ﬂow cytometry. (A) Histograms represent the relative cell number vs. BST-2 ﬂuorescence intensity for the GFP-positive cells. The transfection efﬁciency, as
indicated by the percentage of GFP-positive cells, was approximately 30% for each of the transfections. The black line represents the level of surface BST-2 down-regulation achieved
when Vpu is present. The shaded grey peak represents the levels of surface BST-2 present when transfected with empty vector. (B) Histograms represent the relative cell number vs.
CD4 ﬂuorescence intensity for the GFP-positive cells. The black line represents the level of surface CD4 down-regulation achieved when Vpu is present. The shaded grey peak
represents the levels of surface CD4 present when transfected with empty vector. (C) The bar graph indicates the fractional BST-2 down-regulation achieved by each Vpu tested. The
values were determined as 1− [(Vpu APC-MFI− isotype APC-MFI) /(empty vector APC-MFI− isotype APC-MFI)]; a value of 1.0 indicates complete down-regulation of surface BST-2
(MFI equal to that of the isotype control), whereas a value of 0.0 indicates no down-regulation. (D) The bar graph indicates the fractional CD4 down-regulation achieved by each Vpu
tested. The values were determined as 1− [(Vpu PE-MFI− isotype PE-MFI)/(empty vector PE-MFI− isotype PE-MFI)]; a value of 1.0 indicates complete down-regulation of surface
CD4 (MFI equal to that of the isotype control), whereas a value of 0.0 indicates no down-regulation.
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expressing Vpu-A18H showed surface BST-2 levels comparable to those
observed in cells transfected with the empty vector, although modest
down-regulation of surface BST-2 was detectable at high expression
(GFP) levels (Fig. 1A and data not shown).
Vpu down-regulates CD4 in an endoplasmic reticulum associated
degradation (ERAD)-dependent manner (Binette et al., 2007; Magadan
et al., 2010; Willey et al., 1992). We tested this phenotype to conﬁrm
that each Vpu mutant was not grossly misfolded. Cells were co-
transfectedwith a plasmid expressing codon-optimized Vpu alongwith
a plasmid expressing GFP to indicate transfection efﬁciency. The cells
were then stained for CD4 and analyzed by two-color ﬂow cytometry
(Fig. 1B and D). Each Vpu TMD mutant down-regulated CD4 from the
cell surface, with the exception of Vpu 2/6, conﬁrming the previously
published characterization of the Vpu 2/6 mutant (Schubert et al.,
1996a). Vpu-I17A, -A18H, -W22L, and –S23L all exhibited CD4 down-
regulation similar to or better than wild type Vpu (Fig. 1D).
Vpu-A18H enhances virion release inefﬁciently
As the Vpu TMD mutants induced varying degrees of down-
regulation of cell surface BST-2, we next characterized their abilities toenhance virion release. Cells were transfected with either wild type
pNL4-3 provirus or pvpuDEL-1 (ΔVpu) provirus complemented in
trans with a plasmid expressing the codon-optimized version of each
Vpu mutant-protein. The amount of Vpu expression plasmid was
empirically determined as that which was just sufﬁcient to rescue the
release of ΔVpu to wild type levels. The wild type NL4-3 yielded a
fractional p24 release of 35% compared to 4.2% in the case of ΔVpu,
indicating an 8-fold enhancement of virion release by Vpu expressed
in ciswithin the viral genome (Fig. 2A). When the ΔVpu provirus was
co-transfected with plasmids expressing either wild type Vpu or the
Vpu mutant-proteins, the fractional release of p24 was 29.2% for wild
type Vpu, 28.8% for Vpu-I17A, 24.9% for Vpu-W22L, and 33.3% for Vpu-
S23L, indicating a 6- to 8-fold enhancement of virion release (Fig. 2A).
Complementation of ΔVpu with Vpu-2/6 resulted in a fractional p24
release of 12.7%, an intermediate, 3-fold enhancement consistent with
previous data [Fig. 2A, (Mitchell et al., 2009)].
Complementation of ΔVpu with Vpu-A18H resulted in a fractional
p24 release of only 7.1%, a 1.7-fold enhancement relative to ΔVpu
alone (Fig. 2A). Protein expression was examined by immunoblot to
ensure that each of the Vpu TMD mutants was expressed (Fig. 2B).
Notably, the extent to which each Vpu mutant facilitated down-
regulation of surface BST-2 expression correlated with the extent to
Fig. 2. Vpu-A18H inefﬁciently enhances virion release. (A) Cells (HeLa) were
transfected with either a proviral plasmid expressing wild type HIV-1NL4-3 or a vpu-
negative proviral plasmid vpuDEL-1 (ΔVpu) (1.6 μg). Each of the Vpu mutant-proteins
was expressed in trans (160 ng) with ΔVpu to assess their activity in virion release. The
next day, the fraction of the total p24 capsid antigen produced by the cells that was
secreted into the media was measured by ELISA. The average values from two
independent experiments are graphed; the error bars indicate the actual values
obtained from each experiment. (B) Cells were transfected with plasmid expressing the
indicated codon-optimized Vpu (160 ng). The next day cells were harvested and the
cell lysates were analyzed by immunoblot for Vpu, BST-2, and β-actin.
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that the removal of BST-2 from the cell surface, the site of virion
assembly and budding, is the mechanism by which Vpu enhances
virion release. The data also indicated that the A18H substitution
impairs the activity of Vpu as a BST-2 antagonist.
Vpu-A18H exhibits a cellular distribution consistent with residence in
the endoplasmic reticulum and a reduced interaction with BST-2
To investigate the inability of the A18H mutant to down-regulate
surface BST-2 expression and enhance virion release, we examined
the subcellular distribution of the protein, as well as the other Vpu
mutant-proteins characterized above, using immunoﬂuorescence
microscopy. Cells were transfected to express each of the mutants,
and then 24 hours later ﬁxed, permeabilized, and stained for
intracellular Vpu and BST-2. As described previously (Neil et al.,
2008; Van Damme et al., 2008), BST-2 was distributed throughout the
cytoplasm in punctate structures characteristic of endosomes. In some
cells the protein was relatively concentrated in a juxtanuclear
location. Wild type Vpu was distributed similarly to BST-2, and the
two proteins co-localized extensively in both juxtanuclear and
peripheral endosomal compartments (Fig. 3A).
All of the Vpu TMD mutant-proteins exhibited similar cellular
distributions and appeared to co-localize to a high degree with BST-2,
with the exception of Vpu-A18H (Fig. 3A). Vpu-A18H exhibited a ring-
like perinuclear as well as a reticular cytoplasmic distribution,
consistent with residence in the ER, including the nuclear envelope.
Accordingly, Vpu-A18H co-localized with BST-2 to a lesser degree
than did wild type Vpu or the other Vpu mutants (Fig. 3B, which
shows quantitative image analysis and comparison of the Pearson
coefﬁcient of correlation between the signals for Vpu and BST-2).
To further explore the nature of the impaired antagonism of BST-2
exhibited by Vpu-A18H, co-immunoprecipitation was performed to
measure the degree of interaction between the Vpu proteins and BST-2.
Cells were co-transfected with a plasmid expressing each of the codon-
optimized Vpu TMDmutants together with a plasmid expressing BST-2.
24 hours post-transfection the cells were lysed; BST-2 was immuno-
precipitated; and the captured proteins were analyzed by immunoblot.
Vpu-I17A, -W22L, -S23L, andVpu2/6 co-immunoprecipitatedwithBST-
2 to the same extent as wild type Vpu, while Vpu-A18H exhibited a
reduced interaction (Fig. 3C). This reduced interaction could be solely
the consequence of the mislocalization of Vpu-A18H, or the A18Hsubstitutionmight also directly impair a putative direct interactionwith
the BST-2 TMD. In support of the latter possibility, theVpu-A18F protein
also interacted somewhat less efﬁciently with BST-2 (Fig. 3C), although
its subcellular localization appeared normal (Fig. 6A).
To conﬁrm that the distribution of Vpu-A18H was consistent with
residence in the ER, we co-stained cells for Vpu and calnexin, a
calcium-binding protein located primarily in the ER. Vpu-A18H and
calnexin both exhibited a ring-like perinuclear and reticular cyto-
plasmic distribution, and the two proteins co-localized substantially
(Fig. 4A). In contrast, wild type Vpu and calnexin co-localized less
extensively, and wild type Vpu exhibited, as noted above, a more
endosomal distribution (Fig. 4A).
To conﬁne Vpu to the ER by non-mutational means, we utilized the
ER transport inhibitor brefeldin A (BFA). BFA inhibits guanine
nucleotide exchange factors for ARF-1, blocking the formation of
vesicles that transport proteins out of the ER. BFA caused wild type
Vpu to adopt a similar sub-cellular distribution to Vpu-A18H and to
co-localize more closely with calnexin (Fig. 4A). These microscopic
data supported the conclusion that Vpu-A18H mislocalizes to the ER,
as does wild type Vpu in BFA-treated cells. This mislocalization might
explain Vpu-A18H's impaired down-regulation of cell-surface BST-2,
its inability to enhance virion release, and its reduced interaction with
BST-2.
Vpu fails to down-regulate the expression of BST-2 at the cell surface and
inefﬁciently enhances virion release in the presence of brefeldin A
The preceding data led to the hypothesis that the failure of Vpu to
reach post-ER compartments is associated with a loss of BST-2
antagonism. To test this hypothesis, we assayed Vpu for the ability to
down-regulate surface BST-2 expression and enhance fractional p24
release in the presence of BFA. In the absence of BFA, wild type Vpu
effectively down-regulated the levels of surface BST-2 (compare
surface BST-2 levels in empty vector control to wild type Vpu, in
Fig. 4B). In contrast, Vpu-A18H essentially failed to down-regulate
surface BST-2 (Fig. 4B). BFA alone caused a modest reduction in cell
surface BST-2 expression levels (Fig. 4B; compare empty vector
control surface BST-2 levels in upper and lower panels), but this was
not as great as the reduction caused by Vpu. Importantly, Vpu was
unable to further reduce the levels of BST-2 in the presence of BFA
(Fig. 4B, lower panel). We attempted to evaluate the down-regulation
of CD4 from the cell surface by Vpu in the presence of BFA; however,
BFA treatment alone reduced surface CD4 to undetectable levels (data
not shown). Notably, previously reported data suggests that Vpu-
mediated degradation of CD4 is actually enhanced in the presence of
BFA (Willey et al., 1992). Together, these data suggested that Vpu is
ineffective at down-regulating BST-2 from the surface of cells treated
with BFA, potentially because it is conﬁned to the ER, even though this
treatment enhances the degradation of CD4 by Vpu.
We next determined the inﬂuence of BFA on virion release.
Consistent with its inhibitory effect on the down-regulation of BST-2
by Vpu, BFA also inhibited the enhancement of virion release by Vpu.
In the absence of BFA, Vpu enhanced the fractional p24 release by 8-
fold, consistent with previous data (Fig. 4C). However, in the presence
of BFA, Vpu enhanced fractional p24 release by only 1.5-fold (Fig. 4C;
compare “wt Vpu+BFA” to “ΔVpu+BFA”). Interestingly, although
BFA inhibited the release of virus when Vpu was expressed, it
enhanced (by 2-fold) the fractional release of Δvpu virus (Fig. 4C).
This increase was consistent with the reduced levels of surface BST-2
induced by BFA, resulting in less effective restriction. Overall, these
data on the effect of BFA on virion release in the presence and absence
of Vpu are similar to those previous reported, which were also
obtained using HeLa (BST-2 expressing) cells (Schubert and Strebel,
1994). Vpu-A18H enhanced fractional p24 release by 2.6-fold in the
absence of BFA and had almost no activity in the presence of BFA
(Fig. 4C; compare “ΔVpu+BFA” to “A18H Vpu+BFA”). The decreased
Fig. 3. Vpu-A18H exhibits a cellular distribution consistent with residence in the endoplasmic reticulum. (A) Cells (HeLa) were transfected with plasmid expressing the indicated
codon-optimized Vpu (160 ng). The next day the cells were ﬁxed, permeabilized, and co-stained for Vpu (green) and BST-2 (red). (B) Pearson correlation coefﬁcients were
determined for the co-localization of BST-2 and Vpu for each of the Vpu mutants tested. The bar graph represents at least 10 cells with at least 6 z-planes each and indicates the level
of co-localization between BST-2 and each Vpumutant with standard deviation. (C) Cells (HEK293T) were transfected with a 1:2 plasmid ratio of BST-2 to the indicated Vpu and BST-
2 was immunoprecipitated. The immunoprecipitated proteins were analyzed via immunoblot. The upper panel shows the loading control β-actin and input (expression) controls for
BST-2 and Vpu. The lower panel shows the immunoprecipitation of BST-2 and the co-immunoprecipitation of each Vpu mutant.
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BFA, along with phenotype of the Vpu-A18Hmutant, suggests that the
conﬁnement of Vpu to the ER inhibits its ability to antagonize BST-2.
Endogenously expressed BST-2 exhibits a relatively long steady-state
half-life at the cell surface
The preceding data suggested that Vpu antagonizes BST-2-
mediated restriction within a post-ER compartment. This hypothesis
is in contradistinction to counteraction of restriction by means of ER-
associated degradation of BST-2 (Mangeat et al., 2009). Implicit in the
latter model is the notion that the net removal of BST-2 from the cell
surface is a consequence of a blockade to the deposition of newly
synthesized BST-2, together with the removal of surface BST-2 at an
endogenous turnover rate. To test this, we compared the endogenous
rate of turnover of BST-2 at the cell surface with the rate of removal by
Vpu. To determine the endogenous half-life of surface BST-2, cellswere incubated with BFA or cycloheximide (CHX) for various times,
and then stained for surface BST-2 and analyzed by ﬂow cytometry
(Fig. 5A). BFA was used to block the egress of BST-2 from the ER; this
treatment decreased surface levels to 50% of their initial levels after 9
hours. CHX was used to block de novo synthesis of BST-2 and yielded
similar results; the half-life of surface BST-2 was 8–9 hours (Fig. 5A).
To examine further the steady-state half-life of endogenously
expressed BST-2, we measured the total cellular levels by immunoblot
at various times in the presence of BFA or CHX. In untreated cells, BST-2
levelswere constant throughout thedurationof the experiment, and the
ratio of fully glycosylated BST-2 (26–37 kDa) to the unglycosylated and/
or high mannose forms (19–26 kDa) was stable (Fig. 5B). In the
presence of BFA, unglycosylated and/or high mannose forms of BST-2
accumulated as early as 3 hours after BFA treatment (Fig. 5B) suggested
that BFA effectively blocks egress from the ER. Furthermore, fully
glycosylatedBST-2 levels decreased only after 9 hours of BFA-treatment,
suggesting that endogenous, fully glycosylated BST-2 is relatively stable
Fig. 4. Brefeldin A induces wild type Vpu to adopt a subcellular distribution similar to that of Vpu-A18H. (A) Cells (HeLa) were transfected as in Fig. 3. In the lower panel BFA (10 μg/
ml) was added into the cells immediately following the 4-hour transfection. The next day the cells were ﬁxed, permeabilized, and co-stained for Vpu (green) and calnexin or BST-2 as
indicated (red). (B) Cells (HeLa) were transfected with either an empty vector plasmid or a plasmid expressing codon-optimized Vpu or Vpu-A18H (160 ng of plasmid expressing
codon-optimized Vpu), along with a plasmid expressing GFP (80 ng) as a transfection marker. Immediately following transfection, BFA (10 μg/ml) was added to the cells (+BFA) or
the cells were left untreated (−BFA). The next day, the cells were stained for surface BST-2 and analyzed by two-color ﬂow cytometry. The horizontal black line represents the
isotype control. (C) Cells were transfected with either a proviral plasmid expressing wild type HIV-1NL4-3 or a vpu-negative proviral plasmid vpuDEL-1 (Δvpu; 1.6 μg). Vpu or Vpu-
A18H was expressed in trans (160 ng of plasmid expressing codon-optimized Vpu) along with Δvpu. BFA was added immediately post-transfection (+BFA) or the cells were left
untreated. The next day, the fraction of the total p24 capsid antigen produced by the cells that was secreted into the media was measured by ELISA. The average values from two
independent experiments are graphed; the error bars indicate the actual values obtained from each experiment.
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unglycosylated and/or high mannose forms of BST-2 after 3 hours,
indicating aneffective block todenovo synthesis (Fig. 5B). However, the
levels of mature fully glycosylated BST-2 did not diminish until 9 hoursFig. 5. Vpu-mediated down-regulation occurs more rapidly than can be accounted for by the
for increasing times to BFA (10 μg/ml) or CHX (10 μg/ml) to block deposition of newly synt
stained for BST-2 at the indicated time points and analyzed by ﬂow cytometry. The data gra
cells not treated with BFA or CHX harvested at the same time. (B) The total cellular levels of
the indicated drug (BFA of CHX). BST-2 levels are shown along with β-actin loading controls.
described via ﬂow cytometry but at early time points. The two-color plots from cells harves
0.4%, 1.8%, and 3.4% at each respective time point.of CHX-treatment, suggesting again that endogenous mature BST-2 is
relatively long-lived (Fig. 5B).
We next examined the kinetics of Vpu-mediated removal of BST-2
fromthe cell surface. Cellswere co-transfectedwithaplasmidexpressingendogenous rate of turnover of BST-2 at the cell surface. (A) Cells (HeLa) were exposed
hesized BST-2 on the plasma membrane or de novo synthesis of BST-2. The cells were
phed are the mean ﬂuorescence intensities of BFA- or CHX-treated cells normalized to
BST-2 were examined by immunoblot at the indicated time points post treatment with
(C) The down-regulation of surface BST-2 mediated by Vpu was measured as previously
ted 3, 6, 8 hours after the initiation of transfection are shown; GFP positive events were
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of transfection efﬁciency, as described above. Three hours after the
initiation of the transfection, GFP expression was minimal and no
appreciable down-regulation of BST-2 was observed (Fig. 5C). However,
by 6 hours after initiation of the transfection, we observed a 5-fold
reduction in the levels of BST-2 at the cell surface (Fig. 5C). These data
indicate that the rate and extent of Vpu-mediated down-regulation is
much faster than what can be accounted for by the natural half-life of
BST-2 on the cell surface. The data suggest that Vpu acts to directly
remove BST-2 from the cell surface.
ER conﬁnement of Vpu results in impaired antagonism of BST2
The previous experiments suggested that conﬁnement of Vpu to
the ER, either through chemical means (BFA) or mutagenesis (A18H),
results in impaired antagonism of BST-2. However, the phenotype of
Vpu-A18H could be due not only to mislocalization but also to a
reduced ability to interact with BST-2. To resolve this, we tested two
more Vpu mutants, Vpu-KKDQ and Vpu-A18F. Vpu-KKDQ is identical
to wild type Vpu except that it has a transmembrane protein speciﬁc
ER-retention signal (KKXX) added at the C-terminus (Shikano and Li,
2003). Vpu-A18F is a single residue mutant that we thought might
localize normally but interact poorlywith BST-2. Immunoﬂuorescence
microscopy conﬁrmed that Vpu-KKDQ exhibited an ER-like distribu-
tion and co-localized to an extent with calnexin; this distribution wasFig. 6. Vpu-KKDQ is impaired as a BST-2 antagonist while Vpu-A18F appears similar to wt
optimized Vpu (160 ng). The next day the cells were ﬁxed, permeabilized, and co-stained fo
vector plasmid or a plasmid expressing codon-optimized Vpu (160 ng), along with a plasmid
surface BST-2 and analyzed by two-color ﬂow cytometry. Histograms represent the relative
efﬁciency, as indicated by the percentage of GFP-positive cells, was approximately 30% for
regulation achieved when Vpu is present. The shaded grey peak represents the levels of surfa
as described in panel B. The next day, the cells were stained for surface CD4 and analyzed
ﬂuorescence intensity for the GFP-positive cells. The black line represents the level of surface
the levels of surface CD4 present when transfected with empty vector. (D) The bar graph ind
values were determined as 1− [(Vpu-MFI− isotype MFI)/(empty vector-MFI− isotype-MFI
value of 0 indicates no down-regulation. (E) Cells (HeLa) were transfected with either a p
vpuDEL-1 (ΔVpu) (1.6 μg). Each of the Vpumutant-proteins was expressed in trans (160 ng)
p24 capsid antigen produced by the cells that was secreted into themedia wasmeasured by E
indicate the actual values obtained from each experiment. (F) Cells (HEK293T) were transfec
upper panel shows β-actin as the loading control and input (expression) controls for BS
immunoprecipitation of each Vpu mutant.similar to Vpu-A18H (Fig. 6A). This suggested that the C-terminal ER-
retention signal KKDQ effectively conﬁnes Vpu-KKDQ to the ER. In
contrast, Vpu-A18F exhibited a sub-cellular distribution more typical
of the endosomal system and was similar to wild type Vpu (Fig. 6A).
We evaluated the capacity of Vpu-KKDQ and Vpu-A18F to down-
regulate BST-2 from the cell surface. Vpu-KKDQ was defective for the
down-regulation of BST-2, appearing even more impaired than Vpu-
A18H (Fig. 6B and D). In contrast, Vpu-A18F down-regulated BST-2
with an efﬁciency similar to the wild type (Fig. 6B and D). We also
evaluated the capacity of Vpu-KKDQ and Vpu-A18F to down-regulate
CD4 from the cell surface. Vpu-KKDQ was minimally impaired for the
down-regulation of CD4, appearing less impaired than Vpu-A18H
(Fig. 6C and D). In contrast, Vpu-A18F down-regulated CD4 with
efﬁciency similar to wild type Vpu (Fig. 6C and D).
We next examined each Vpu's ability to enhance virion release
(Fig. 6D). Vpu-KKDQ was virtually inactive for enhancement of virion
release, while VpuA18H enhanced virion release less than 2-fold
(Fig. 6E). In contrast, Vpu-A18F enhanced virion release by 6-fold, an
activity almost equal to that of wild type Vpu (Fig. 6E). Western blot
conﬁrmed that each of these Vpu mutants was expressed, although
Vpu-KKDQwas expressed at levels slightly lower than that of the wild
type (Figs. 6F and 3C regarding Vpu-A18F). Immunoprecipitation data
indicated that the interaction between BST-2 and Vpu-KKDQ or Vpu-
A18H was reduced relative to wild type Vpu (Fig. 6F). These data
suggest that Vpu cannot effectively antagonize BST-2 when conﬁnedVpu. (A) Cells (HeLa) were transfected with plasmid expressing the indicated codon-
r Vpu (green) and BST-2 (red). (B) Cells (HeLa) were transfected with either an empty
expressing GFP (80 ng) as a transfectionmarker. The next day, the cells were stained for
cell number vs. BST-2 ﬂuorescence intensity for the GFP-positive cells. The transfection
each of the transfections. The black line represents the level of surface BST-2 down-
ce BST-2 present when transfected with empty vector. (C) Cells (HeLa) were transfected
by two-color ﬂow cytometry. Histograms represent the relative cell number vs. CD4
CD4 down-regulation achieved when Vpu is present. The shaded grey peak represents
icates the fractional BST-2 and CD4 down-regulation achieved by each Vpu tested. The
)]; value of 1.0 indicates complete down-regulation of surface BST-2 or CD4, whereas a
roviral plasmid expressing wild type HIV-1NL4-3 or a vpu-negative proviral plasmid
with ΔVpu to assess their activity in virion release. The next day, the fraction of the total
LISA. The average values from two independent experiments are graphed; the error bars
ted as in Fig. 3C. The immunoprecipitated proteins were analyzed via immunoblot. The
T-2 and Vpu. The lower panel shows the immunoprecipitation of BST-2 and the co-
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suggest that even when the Vpu TMD sequence is intact, conﬁnement
to the ER reduces the potential for Vpu to bind to BST-2.
To assess whether the Vpu-A18H TMD was intrinsically impaired
in its potential to interact with the TMD of BST-2, we performed
molecular dynamic (MD) simulations on the individual TMDs within
hydrated lipid bilayers followed by a packing protocol to generate
dimeric assemblies (Fig. 7) (Kruger and Fischer, 2008, 2009). The
TMDs maintained a stable helical conformation throughout a short
10 ns MD simulation after generating the ideal helices; the RMSD
values leveled off after an initial rise within the ﬁrst 1000 ps and
remained in a range of 0.1 to 0.2 nm for BST-2 and 0.15 and 3.0 nm for
the Vpu and Vpu-A18H helices (Supplemental Fig. 1).
Packing of BST-2 with wild type Vpu led to a lowest energy
structure with an interhelical distance of about 16 Å, rotational angle
of 90°, a positive tilt of 60°, and a potential energy of -381.8 kcal/mol
(Fig. 7A, Suppl. 1C). The ﬁve most stable BST-2/wild type Vpu
structures had potential energies of less than or equal to -347.1 kcal/
mol. Replacing alanine-18 with an uncharged histidine yielded a
lowest energy structure of -341.4 cal/mol with a minimum distance of
10 Å, rotational angle of 90° and a tilt of 18° (Fig. 7B, Suppl. 1D). The
next most stable BST-2/Vpu-A18H assembly had a minimum distance
of 13 Å and a potential energy of -323.1 kcal/mol. All other structures
of BST-2/Vpu-A18H were above -300 kcal/mol. The packing of BST-2
with wild type Vpu in these simulations was driven by contact of
hydrophobic residues (Fig. 7C),whereas in the lowest energy structure
of BST-2/Vpu-A18H the histidine faces the backbone of BST-2 (Fig. 7D).
Overall, these simulations indicated that Vpu-A18H has the potential
to interact with BST-2 via its TMD, although the interaction is likely to
be somewhat less stable than in the case of wild type Vpu.
Discussion
We show here that a single amino acid substitution in the trans-
membrane domain of Vpu (A18H) is sufﬁcient to cause abnormalFig. 7. Interaction potential of BST-2 with Vpu and Vpu-A18H. Interaction energies of the B
distance as determined by a packing protocol using MOE script language. Dots represent ind
lowest energy structures of BST-2/Vpu (C) and BST-2/Vpu-A18H (D) in the “Gaussian con
hydrophobic residues are shown in green, prolines in violet, alanines in orange, BST-2-G25 in
“A” indicates four alanines in the Vpu (A7, A10, A14, and A18) that are on one face of the Tretention of the protein in the ER. This mislocalization is associated
with defects in the ability of Vpu to remove the interferon-induced
tethering factor BST-2 from the cell surface and in the ability of Vpu to
enhance the release of virions. Mimicry of these phenomena by
treatment of cells with the fungal metabolite BFA, which blocks the
egress of proteins from the ER, or by the addition of an ER retention
signal to the C-terminus of Vpu, supports the notion that Vpu
counteracts BST-2 from within post-ER membrane systems. In
support of a model in which Vpu directly removes BST-2 from the
plasma membrane, we observed that the half-life of BST-2 on the cell
surface is too long to allow ER-degradation or sequestration along the
biosynthetic/exocytic pathway to fully account for the speed and
extent of Vpu-mediated down-regulation. The conservation of residue
A18 among groupMHIV-1 Vpu's, and its frequent absence from group
O and SIV Vpu's that are unable to counteract BST-2, supports a
general importance of this TMD residue for Vpu function [Fig. 8 and
(Sauter et al., 2009)].
Prior to the identiﬁcation of BST-2 as the restriction factor
counteracted by Vpu, the cation selective ion-channel activity of Vpu
homo-oligomers was presumed to be the determinant of enhanced
virion release (Lopez et al., 2002; Schubert et al., 1996a,b). Even after
the role of the Vpu TMD in the down-regulation and antagonism of
BST-2 was reported (Van Damme et al., 2008), the notion that ion
channel activity could underlie an effect of Vpu on the endosomal
trafﬁcking of BST-2 remained plausible.
However, the data presented here suggest that the enhanced virion
release mediated by Vpu is likely independent of ion-channel activity.
The I17A substitution studied here was intended to affect a hinge
region or kink in the Vpu TMDα-helix (Park et al., 2003). Although the
ion-channel activity of the Vpu-I17A has not been determined, Vpu-
I17A effectively enhanced virion release and down-regulated BST-2
from the cell surface. Furthermore, Vpu-I17A exhibited a similar
subcellular distribution to wild type Vpu and co-localized with BST-2
within endosomes. The frequency of the polymorphism I17A was the
highest of the four mutants tested (8%), supporting our observationsST-2/Vpu (A) and BST-2/Vpu-A18H (B) TMD assemblies in relation to their interhelical
ividual structures. Arrows indicate the lowest energy structures. Representation of the
tact” mode of the MOE suite. The backbone is indicated in a ribbon representation;
yellow-orange, His-18 in red, and a hydrophilic motif of Vpu, EYRK, in blue. The boxed
MD helix.
Fig. 8. Amino acid frequencies at p18 in HIV-1 and SIVcpz Vpu proteins. The overall height of each bar indicates level of sequence conservation (difference between maximum
possible entropy and observed entropy) at Vpu position 18 within each lentiviral lineage (correcting for small sample size). The relative heights within the stack indicate the relative
frequency of each amino acid, based on all available sequences in the Los Alamos HIV Sequence Database (only a single sequence per host individual was included in the analysis).
Alanine is represented by the color orange, and the remaining residues are colored according to the “Cinema” amino acid labeling scheme as shown. A complete list of residues
appearing in each lineage is included under each stack, ordered by frequency (hyphens represent deletions). Frequencies within the entire HIV-1M-group including recombinants
are represented in the ﬁrst column (“ALL”), and subsequent columns represent group M subtypes A-G, group N, group O, and SIVcpz. Group O HIV-1 and SIVcpz Vpu proteins
infrequently encode A18 are generally ineffective antagonists of BST-2 (Sauter et al., 2009).
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W22L was previously characterized as a functional ion-channel,
although rather than oscillating rapidly between open and closed
conformations, the transitions between the two conformations are
prolonged (Mehnert et al., 2008). Nevertheless, Vpu-W22L efﬁciently
down-regulated BST-2 from the cell surface; it efﬁciently enhanced
virion release; and it co-localized extensivelywith BST-2.We observed
thatW22was very highly conserved among groupMVpu's (frequency
greater than 99%). This conservation suggests that the very subtle
defects of Vpu-W22L in the down-regulation of BST-2 from the cell
surface and in the enhancement of virion release may be important in
vivo.
Strikingly, Vpu-S23L was previously characterized as defective for
ion-channel activity (Mehnert et al., 2008), yet it robustly down-
regulated BST-2 from the cell surface; it enhanced virion release to the
same extent as wild type Vpu; and it co-localized and interacted with
BST-2. These results suggest that Vpu's ion channel activity is not
necessary for the down-regulation of BST-2 and the enhancement of
virion release. The existence of naturally occurring polymorphisms at
this position (in particular isoleucine in 11% of groupM Vpu's) further
supports the notion that Vpu's ion-channel activity may not be
necessary for optimal virion release.
Vpu-A18H was ﬁrst conceived to mimic the Inﬂuenza virus M2
protein ion-channel and allow Vpu's channel activity to be modulated
by adamantane drugs (Hout et al., 2006a,b). The M2 protein forms a
proton channel, and it facilitates an essential step of the Inﬂuenzavirus life-cycle by promoting acidiﬁcation and uncoating of the virion
(Henkel et al., 1999; Henkel and Weisz, 1998; Sakaguchi et al., 1996).
Although the ion-channel activity of Vpu-A18H has not been
determined, its presence in an SHIV background rendered the virus
susceptible to rimantadine when used at high concentrations during
spreading infections (Hout et al., 2006a). This result seems at some
odds with the data herein, in which the A18H substitution itself
impaired Vpu's ability to enhance virion release, even in the absence
of an adamantane. To reconcile these ﬁndings, we note that Vpu-A18H
retained amodest ability to down-regulate BST-2 from the cell surface
at the very highest levels of transfection (as measured by GFP
intensity). Furthermore, Vpu-A18H was not completely devoid of
virologic activity; rather it enhanced virion release by only 2-fold
compared to the 7- to 8-fold increase observed for the wild type
protein.
Unexpectedly, microscopic data indicated that Vpu-A18H remains
largely trapped in the ER and fails to efﬁciently access the trans-Golgi
network and the endosomal system. How does a single amino acid
substitution in the TMD affect the steady-state subcellular localization
of Vpu? Structural analysis of the Vpu TMD in artiﬁcial lipid bilayers
suggests that the A18H substitution increases the length of the α-
helical TMD (Park and Opella, 2007). This in turn increases the tilt
angle of the helix relative to the lipid bilayer, at least in artiﬁcial
bilayers of ﬁxed composition (Park and Opella, 2007). Since the ER,
Golgi, andplasmamembranes are of unequal thickness due to different
contents of cholesterol, a change in TMD length could conceivably alter
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but shorter rather than longer TMD lengths are associated with
retention in the ER (Bretscher and Munro, 1993; Pelham and Munro,
1993; Yang et al., 1997).
Remarkably, a precedent exists for the ER-retention induced by the
A18H substitution: the introduction of single charged residues or
histidines within the TMD of the IL-2 receptorα chain (Tac antigen), a
protein normally resident on the plasma membrane, induces ER-
retention, although themechanismof this effect is obscure (Bonifacino
et al., 1991). Here, this single substitution in the Vpu TMD was
similarly sufﬁcient to induce ER-retention, and to adversely affect BST-
2 antagonism.
Apparently, Vpu is rendered largely inactive for down-regulating
BST-2 from the cell surface and enhancing virion release when it is
trapped in the ER. However, since Vpu-A18H co-localized poorly with
BST-2, an alternative explanation is that the A18H substitution directly
disrupts the reported interaction between the two proteins (Douglas
et al., 2009;Mangeat et al., 2009; Rong et al., 2009). Residue A18 is part
of an AxxxAxxxA sequence that is relatively well conserved among
groupM and N Vpu's (Fig. 8), proteins that are generally active as BST-
2 antagonists (Sauter et al., 2009). GxxxG and AxxxA motifs are
thought to facilitate backbone interactions between α-helixes within
lipid bilayers (Senes et al., 2004), and so the A18H substitution could
potentially affect directly the interaction with BST-2. Similarly, the
increased tilt angle of the Vpu-A18HTMD could potentially disrupt the
interaction with BST-2 (Park and Opella, 2007). In this regard,
computational modeling indicated that Vpu-A18H has the potential
to interactwithBST-2 via its TMD, although the interaction is predicted
to be somewhat less stable thanwild type Vpu. In contrast to histidine,
the substitution of A18 with phenylalanine (Vpu-A18F) minimally
disrupted Vpu activity. This mutant localized normally, although its
ability to interactwith BST-2wasmodestly impaired. Altogether, these
data suggest that the primary defect in Vpu-A18H is subcellular
mislocalization. The data also suggest that an alanine at position 18 is
not required for function, although a histidine is clearly non-
permissive. Recent data suggest that transmembrane domain residues
A14 and W22 inﬂuence BST-2 antagonism more signiﬁcantly than
residue A18 (Vigan and Neil, 2010).
Blocking the egress of proteins from the ER by treating cells with
BFA largely mimicked the effect of the A18H substitution. Morpho-
logic and biochemical evidence suggested that BFA blocked the egress
of both Vpu and BST-2 from the ER, and this rendered Vpu unable to
down-regulate BST-2 from the cell surface or to enhance virion
release. Interestingly, BFA itself modestly mimicked the effect of Vpu;
such mimicry was expected since the block to egress from the ER
modestly decreased the levels of BST-2 at the cell surface, though this
effect was less than the effect of Vpu.
Consistent with the notion that Vpu antagonizes BST-2 from a
post-ER compartment, we observed that the half-life of cell surface
BST-2 is too long to enable degradation or trapping along the
biosynthetic pathway to account for Vpu activity. The half-life of
endogenously-expressed surface BST-2 in BFA- and CHX-treated cells
was between 8 and 9 hours. Given the rapid rate of endocytosis of
BST-2, in which 50% of the protein is internalized from the cell surface
within 20–40 minutes (Mitchell et al., 2009), the long surface half life
measured here suggests that internalized BST-2 is efﬁciently recycled
to the plasma membrane, with only a fraction entering an endosomal
degradative pathway. Put another way, 8–9 hours is the half-life of
BST-2 on the cell surface when the transport of newly synthesized
BST-2 to the plasma membrane is blocked or de novo synthesis is
inhibited. Despite this, Vpu mediated a 5-fold decrease in the levels of
BST-2 within as little as 6 hours. Given the 8- to 9-hour half-life of
surface BST-2, Vpu cannot mediate such a rapid and extensive effect
solely by degrading newly synthesized BST-2 via the ERAD pathway or
by trapping it in the TGN or other exocytic membranes (Dube et al.,
2010; Mangeat et al., 2009).Instead, our data suggest that Vpu removes BST-2 directly from the
plasma membrane to enhance virion release. This conclusion is
consistent with the morphologic data indicating that Vpu functions
fromwithin post-ER, endosomal membranes. It is also consistent with
the previous observation of a role for the endocytic clathrin adaptor
AP-2 in the Vpu-mediated down-regulation of BST-2 and the
hypothesis that Vpu inhibits the recycling of BST-2 (Mitchell et al.,
2009). The data herein indicate that the down-regulation of BST-2
occurs very rapidly, a condition likely necessary so that Vpu, which is
expressed relatively late as a Rev-dependent protein, can effectively
remove BST-2 before the onset of viral budding.
Taken together, the data presented here show that Vpu-mediated
down-regulation of surface BST-2 correlates with enhanced virion
release and likely occurs independently of Vpu ion-channel activity.
The Vpu-mediated antagonism of BST-2 likely occurs in post-ER
endosomal compartments and at a rate consistent with the direct
removal of BST-2 from the cell surface. This removal is extremely
rapid, consistent with the hypothesis that it is the primarymechanism
of the counteraction of restriction.
Materials and methods
Plasmids, antibodies, and reagents
pcDNA3.1 (Invitrogen, Carlsbad, CA) was used as an empty vector
control. Proviral plasmid pNL4-3 was obtained from the National
Institute of Health (NIH) AIDS Research & Reference Reagent Program.
The ΔVpu mutant of pNL4-3 (vpuDEL-1) and the pcDNA3.1-based
plasmid expressing codon optimized Vpu (pVphu) were provided by
Dr. Klaus Strebel. Mutations in pVphu were introduced using the
Stratagene (La Jolla, CA) QuikChange kit and conﬁrmed by nucleotide
sequencing. The plasmid expressing GFP (pCG-GFP) was provided by
Dr. Jacek Skowronski. The murine monoclonal antibody to BST-2/
HM1.24/CD317 was a gift from Chugai Pharmaceutical Co., Kanagawa,
Japan. An isotype control antibody, IgG2a, a secondary goat anti-
mouse IgG antibody conjugated to allophycocyanin (APC), murine
monoclonal antibody to BST-2 (hCD317 RS38E) directly conjugated to
Alexa 647, and an isotype control Alexa 647-direct conjugate were
obtained from BioLegend (San Diego, CA). The murine monoclonal
antibody to human CD4 directly conjugated to PE and a PE-conjugated
isotype control were obtained from BD Biosciences (San Jose, CA).
Rabbit antiserum speciﬁc to HIV-1 Vpu and human BST-2 was
obtained from the NIH AIDS Research & Reference Reagent Program
and contributed by Dr. Klaus Strebel. The murine monoclonal
antibody to Calnexin was obtained from BD Biosciences (San Jose,
CA). The secondary antibodies used for immunoﬂuorescence were
obtained from Jackson ImmunoResearch (West Grove, PA). Brefeldin
A was obtained from Sigma-Aldrich (St. Louis, MO).
Cells and transfections
The HeLa cells used in most of this study, clone P4.R5, express both
CD4 and CCR5 were obtained from Dr. Ned Landau; these cells are a
derivative of clone P4 and were maintained in DMEM supplemented
with 10% FBS, penicillin/streptomycin, and puromycin. The HeLa cells
used to evaluate the effectiveness of BFA in blocking newly syn-
thesized CD4 from reaching the cell surface (clone Z24) do not express
CD4; were provided by Dr. Chris Aiken; and were maintained in
DMEM supplementedwith 10% FBS, and penicillin/streptomycin. Cells
were transfected with Lipofectamine 2000 (Invitrogen) according to
the supplied directions. For the experiments evaluating BST-2 surface
down-regulation and protein expression, 160 ng of pVphu or
pcDNA3.1 along with 40 ng of pCG-GFP were used to transfect 1.2
million HeLa P4.R5 cells in wells of a 6-well plate. For experiments
evaluating fractional virion release, 1.6 μg of proviral plasmid pNL4-3
or vpuDEL-1 along with 160 ng of the indicated pVphu plasmid were
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plate. For experiments simultaneously evaluating the surface down-
regulation of BST-2 and CD4, 200 ng of pVphu along with 100 ng of
pCG-GFPwere used to transfect 0.5 million HeLa P4.R5 cells in wells of
a 12-well plate.
Flow cytometry
For analysis of surface levels of BST-2, cells were stained before
ﬁxation in phosphate buffered saline (PBS) including sodium azide,
and 2% FBS at 4 °C using an indirect method to detect BST-2. The
primary murine HM1.24 monoclonal antibody (0.1 μg/ml) was
followed by a secondary goat anti-mouse IgG conjugated to APC. All
samples were analyzed using two-color ﬂow cytometry. The BST-2
gate was set using an isotype (IgG2a) control as the primary antibody,
and the gate for GFP was set using non-GFP expressing cells. For
simultaneous analysis of surface levels of BST-2 and CD4, cells were
stained for 1 hour at 4 °C before ﬁxation in phosphate buffered saline
(PBS) including sodium azide and 2% FBS using a murine hCD317
monoclonal antibody directly conjugated to Alexa 647- (0.1 μg/ml)
and a murine hCD4 monoclonal antibody directly conjugated to PE
(0.1 μg/ml). All samples were analyzed using three-color ﬂow
cytometry. The BST-2 gate was set using an isotype Alexa 647 direct
conjugate control; the CD4 gate was set using the isotype PE direct
conjugate control; and the gate for GFP was set using non-GFP
expressing cells. Data proﬁles and mean ﬂuorescence intensity (MFI)
values were generated using FlowJo software (Tree Star, Inc, Ashland,
OR).
Virion-release assays
A p24 antigen capture ELISA (Perkin-Elmer) was used to
determine the concentration of viral capsid protein in culture
supernatants that were ﬁrst clariﬁed by centrifugation at 400g as
well as the concentration of capsid protein in detergent lysates (0.5%
Triton-X-100 in PBS) of the adherent cells. The fractional release of
p24 capsid was determined as the concentration of p24 antigen in the
supernatants divided by the total concentration of p24 antigen in both
the supernatants and cell lysates.
Immunoﬂuorescence microscopy
Cells were stained for BST-2, Calnexin, and HIV-1 Vpu using the
antibodies above after ﬁxation in 3% formaldehyde and permeabiliza-
tion using 0.1% NP-40, both in PBS, as previously described. Images
were obtained using a ﬂuorescence microscope with the 100×
objective (Olympus, Melville, NY). For each ﬁeld, a Z-series of images
was collected, and the data were processed using a nearest neighbors
deconvolution algorithm (Slidebook software, Intelligent Imaging
Innovations, Inc). Composite multi-color images of single optical
sections were assembled using Adobe Photoshop software.
Western blot and immunoprecipitations
Cells were suspended in Laemmli buffer and boiled for 10 minutes.
The samples were then resolved on 12% SDS-denaturing polyacryl-
amide gels (Bio-Rad, Hercules, CA) and subsequently transferred to
polyvinylidene diﬂuoride membranes. Immunoblotting was per-
formed with the antibodies to BST-2 and Vpu described above or
with antibody to β-actin (Sigma). Detection was performed using a
goat anti-mouse antibody conjugated to horseradish peroxidase (Bio-
Rad) or a donkey anti-rabbit antibody conjugated to horseradish
peroxidase (Pierce Protein Research Products, Rockford, IL), followed
by development with enhanced chemiluminescence reagent (GE
Healthcare, Piscataway, NJ).For IP, 90-95% conﬂuent 293 T cells were transfected with 7.5 μg
BST-2 and 15 μg of Vpu-expressing plasmids, in 10 cm2 dishes.
24 hours later, the cells were collected and lysed in buffer (50 mM
Tris–HCl, pH7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100)
supplemented with protease inhibitor cocktail (Roche Diagnostics,
Indianapolis, IN) for 30 minutes on ice and 30 minutes at room
temperature (RT). Cell lysates were cleared by centrifugation at
16,000g at 4 °C for 10 minutes, then incubated with anti-BST-2
antibody pre-bound to anti-mouse IgG coated magnetic Dynabeads
(Invitrogen Dynal, Oslo, Norway), for 2 hours at 4 °C. The ratio of cells/
anti-BST-2 antibody/magnetic beads was 1×10 cm2 dish/2 μg anti-
BST-2/200×105 beads. Beads were washed three times with buffer
(lysis buffer except with 250 mM NaCl), bound proteins were eluted
with 30 μl Laemmli buffer, and subjected to Western blot analysis.
Modeling interaction potential of BST-2 and Vpu-A18H
Ideal helices of BST-2 (LLGIGILVLLIIVILGVPLIIF) and Vpu-WT
(MVPIIVAIVA10 LVVAIIIAIV20VWSIVIIEYR30KI, GenBank: AAB59750.1,
www.ncbi.nlm.nih.gov) and the mutant Vpu-A18H containing the
TMDs of the respective proteins were created using integrated protein
builder of MOE (www.chemcomp.com) (Kruger and Fischer, 2009).
After a short equilibration in a fully hydrated lipid bilayer using
molecular dynamics (MD) simulations (GROMACS-3.3), an averaged
structure was used to generate the dimers (see supplemental
materials for details).
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.virol.2010.12.038.
Determination of HIV-1 and SIV Vpu polymorphism frequencies
All available Vpu sequences were downloaded from the Los
Alamos National Laboratory HIV Sequence Database (http://www.
hiv.lanl.gov/). Single representative sequences for each host individ-
ual were chosen arbitrarily for analysis when multiple sequences
were available. Multalin (Corpet, 1988) was used to generate all
multiple sequence alignments. LogoBar v1.0 (Perez-Bercoff et al.,
2006) was implemented to examine site-speciﬁc Shannon entropy
and relative amino acid frequencies at Vpu position 18 in HIV-1 and
SIV taxa. The height of each individual bar represents the difference
between the maximum possible entropy and the entropy of the
observed amino acid distribution (correcting for small sample size).
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